Autodesk Up Over 8%, On Track for Largest Percent Increase Since August 2025 -- Data Talk
Dow Jones2026/11/04 18:17Autodesk, Inc. (ADSK) is currently at $273.20, up $20.89 or 8.28%
--Would be highest close since Jan. 12, 2026, when it closed at $277.89
--On pace for largest percent increase since Aug. 29, 2025, when it rose 9.09%
--Currently up three of the past four days
--Down 7.7% year-to-date; on pace for worst year since 2022, when it fell 33.54%
--Down 20.18% from its all-time closing high of $342.27 on Aug. 25, 2021
--Down 9.22% from 52 weeks ago (Nov. 5, 2025), when it closed at $300.96
--Down 11.94% from its 52-week closing high of $310.25 on Dec. 2, 2025
--Up 45.54% from its 52-week closing low of $187.72 on June 22, 2026
--Traded as high as $273.72; highest intraday level since Jan. 26, 2026, when it hit $274.25
--Up 8.48% at today's intraday high; largest intraday percent increase since Sept. 14, 2026, when it rose as much as 8.49%
--Eighth best performer in the Nasdaq 100 today
All data as of 1:15:27 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
November 04, 2026 13:17 ET (18:17 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
